Previous Page
33 nanotimes Companies Facts
president and CEO of pSivida. "We have designed it to allow the insertion of drug delivery devices, such as our Medidur(TM) implant, through a far smaller needle than was previously possible and to require significantly less force to administer. We anticipate using this new inserter in the planned Phase III trials of our posterior uveitis insert."
Moreover, pSivida announced the National Authority of Medicines and Health Products (Autoridade Nacional do Medicamento e Produtos de Saúde, Infarmed) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. This marketing authorization follows the completion of the Decentralized Regulatory Procedure (DCP) in the European Union (EU), in which the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, serving as the Reference Member State (RMS), delivered a positive outcome for ILUVIEN along with six Concerned Members States (CMS), specifically Austria, France, Germany, Italy, Portugal and Spain. The Portuguese authorization is the third national approval in the EU, preceded by Austria and the UK.
"We are pleased our product has received marketing authorization in Portugal. We now have marketing authorization in three of the seven targeted EU countries," said Dr. Paul Ashton, president and chief executive officer of pSivida . "We look forward to ILUVIEN(R) receiving approval in the four remaining CMS countries, France, Germany, Italy and Spain, in the coming months." The International Diabetes Federation estimates that more than 1,000,000 people are currently living with diabetes in Portugal, and according to Alimera’s estimates, more than 55,000 people suffer from vision loss associated with DME. pSivida also announced the enrollment of the first patient in an investigator-sponsored clinical trial of its injectable sustained release device in posterior uveitis.
QED Technologies International Inc, (QED), pioneer and exclusive provider of Magnetorheological Finishing (MRF(R)) polishing and Subaperture Stitching Interferometry (SSI(R)) metrology platforms for the precision optics industry, announced the release of its QED Interferometer for Stitching (QIS(TM)) system. The QIS system, developed and manufactured by QED Technologies, provides greater capabilities to QED‘s metrology product line and is optimized for stitching.
Samsung Electronics Co. has begun producing the industry’s first four gigabit (Gb), low power double-data-rate 2 (LPDDR2) memory using 20nm class technology. The mobile DRAM (dynamic random access memory) chip, which went into mass production last month, will help the market to deliver advanced devices that are faster, lighter and provide longer battery life than today’s mobile devices.